Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABY-029 Fluorescence in High-Grade Glioma
NCT07063693Phase 1Recruiting
- Sponsor
- Dartmouth Health
- Start
- Feb 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABY-029 in glioma (2 arms), sponsored by Dartmouth Health. Primary endpoints: Adverse events related to ABY-029 at 1 month and False negative rate of ABY-029 fluorescence up to 3 months. Started Feb 2026; status: recruiting.
02
Drugs
ABY-029
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07063693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063693.